The parties intend to finalize their partnership, which extends to Europe, including Russia and the CIS, Latin America, Australia, and New Zealand, in Q1 2023.
Under the terms of the agreement, Mithra is eligible to receive upfront payments totaling EUR 55m as well as EUR 15m in additional milestone payments subject to regulatory achievements and "tiered low double-digit" royalties depending on net sales.
Mithra announced positive top-line results from Donesta phase 3 studies in menopausal women in January 2022.